Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.


SecurityTRVN / Trevena, Inc. (89532E109)
President & CEOGOWEN MAXINE
IndustryPharmaceutical Preparations
Institutional Owners82
Institutional Shares37,008,970 - 54.45%
Common Shares Outstanding67,968,713 shares (as of 2018-03-31)
Institutional Value$ 96,361,000 USD

Institutional Stock Ownership and Shareholders()

TRVN / Trevena, Inc. Institutional Ownership

Trevena, Inc. (NASDAQ:TRVN) has 82 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 37,008,970 shares. Largest shareholders include Wellington Management Group LLP, FMR LLC / Fidelity, NEA Management Company, LLC, BlackRock Inc., Vanguard Group Inc, BlackRock Fund Advisors, Polaris Venture Management Co. V, L.L.C., Northpointe Capital Llc, Vivo Capital, LLC, and BlackRock Institutional Trust Company, N.A..
Trevena, Inc. (NASDAQ:TRVN) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/trvn"><img src="https://images.fintel.io/us-trvn-so.png" alt="TRVN / Trevena, Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2017-02-10 13F-HR BlackRock Advisors LLC 127,865 75,298 -41.11 863 443 -48.67
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. Call 1,300 8,900 584.62 2 15 650.00
2018-05-15 13F-HR Palo Alto Investors, LLC 341,300 341,300 0.00 546 560 2.56
2018-05-07 13F-HR SCHWAB CHARLES INVESTMENT MANAGEMENT INC 93,162 144,362 54.96 150 237 58.00
2018-05-15 13F-HR DEUTSCHE BANK AG\ 130,463 66,891 -48.73 208 108 -48.08
2018-05-02 13F-HR RHUMBLINE ADVISERS 56,230 54,730 -2.67 90 90 0.00
2018-05-15 13F-HR STATE STREET CORP 822,743 913,541 11.04 1,317 1,495 13.52
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. 4,739 0 -100.00 8 0 -100.00
2018-04-11 13F-HR NORTHPOINTE CAPITAL LLC 1,772,557 1,905,458 7.50 2,836 3,125 10.19
2018-05-04 13F-HR Polaris Venture Management Co. V, L.L.C. 2,053,540 2,053,540 0.00 3,286 3,368 2.50
2018-05-11 13F-HR Russell Investments Group, Ltd. 200 0 -100.00 0 0
2018-05-03 13F-HR SG Americas Securities, LLC 11,973 25,377 111.95 19 42 121.05
2018-05-17 13F-HR Legal & General Group Plc 17,643 12,603 -28.57 29 21 -27.59
2018-05-15 13F-HR Parallax Volatility Advisers, L.P. 8,526 0 -100.00 14 0 -100.00
2018-05-15 13F-HR ADVANTAGE INVESTMENT MANAGEMENT, LLC 0 500 0 1
2018-05-10 13F-HR First Personal Financial Services 380 230 -39.47 1 0 -100.00
2018-04-24 13F-HR McAdam, LLC 52 0
2018-05-15 13F-HR HighTower Advisors, LLC 15,005 15,005 0.00 24 25 4.17
2017-02-10 13F-HR BlackRock Group LTD 8,422 9,745 15.71 57 58 1.75
2018-05-15 13F-HR MILLENNIUM MANAGEMENT LLC 81,286 473,691 482.75 130 777 497.69
2018-05-10 13F-HR JP Morgan Chase & Co 12,128 89,228 635.72 19 146 668.42
2017-04-21 13F-HR MAGEE THOMSON INVESTMENT PARTNERS LLC 113 0 -100.00 1 0 -100.00
2018-05-14 13F-HR Virtu Financial LLC 191,701 0 -100.00 307 0 -100.00
2018-07-13 13F-HR BANK OF MONTREAL /CAN/ 1,146 1,146 0.00 2 2 0.00
2018-05-14 13F-HR TEACHERS ADVISORS INC 106,642 106,642 0.00 171 175 2.34
2018-05-15 13F-HR Bank of New York Mellon Corp 181,722 192,736 6.06 291 316 8.59
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. Put 1,000 0 -100.00 2 0 -100.00
2018-04-26 13F-HR SIMPLEX TRADING, LLC Put 27 11 -59.26 2 1 -50.00
2018-05-15 13F-HR Vivo Capital, LLC 1,728,000 1,728,000 0.00 2,765 2,834 2.50
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 989,828 1,014,704 2.51 6,681 5,966 -10.70
2018-05-10 13F-HR NEA Management Company, LLC 3,811,691 3,811,691 0.00 6,099 6,251 2.49
2018-05-15 13F-HR BALYASNY ASSET MANAGEMENT LLC 46,148 35,508 -23.06 74 58 -21.62
2018-05-15 13F-HR Wellington Management Group LLP 5,866,580 6,777,154 15.52 9,386 11,115 18.42
2018-05-15 13F-HR HARBOURVEST PARTNERS LLC 233,850 233,850 0.00 374 384 2.67
2018-05-15 13F-HR Paloma Partners Management Co 45,600 0 -100.00 73 0 -100.00
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 75,564 0 -100.00 121 0 -100.00
2018-05-15 13F-HR National Asset Management, Inc. 11,105 0 -100.00 18 0 -100.00
2018-05-15 13F-HR VANGUARD GROUP INC 2,288,670 2,298,196 0.42 3,662 3,769 2.92
2018-05-15 13F-HR CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 90,107 89,161 -1.05 144 146 1.39
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Put 36,300 14,400 -60.33 58 24 -58.62
2018-05-15 13F-HR QS Investors, LLC 173,811 156,948 -9.70 278 257 -7.55
2017-02-10 13F-HR BlackRock Investment Management, LLC 172,290 174,245 1.13 1,163 1,025 -11.87
2018-05-15 13F-HR Tower Research Capital LLC (TRC) 2,141 3,783 76.69 3 6 100.00
2017-05-15 13F-HR R&F Capital Advisors LP 25,085 92
2018-05-14 13F-HR MORGAN STANLEY 111,837 121,694 8.81 179 200 11.73
2018-05-15 13F-HR Jefferies Group LLC 14,500 0 -100.00 23 0 -100.00
2018-05-15 13F-HR HIGHBRIDGE CAPITAL MANAGEMENT LLC 16,992 0 -100.00 27 0 -100.00
2018-05-11 13F-HR CITADEL ADVISORS LLC 14,695 24
2018-05-14 13F-HR/A CITADEL ADVISORS LLC 10,683 14,695 37.55 17 24 41.18
2018-05-11 13F-HR GSA CAPITAL PARTNERS LLP 149,947 122,947 -18.01 240 202 -15.83
2018-05-09 13F-HR BlackRock Inc. 3,172,477 3,164,387 -0.26 5,077 5,190 2.23
2018-05-11 13F-HR PNC FINANCIAL SERVICES GROUP, INC. 0 1,000 0 2
2018-04-19 13F-HR Endurance Wealth Management, Inc. 10,000 11,000 10.00 16 18 12.50
2018-05-08 13F-HR Aperio Group, LLC 10,248 12,548 22.44 16 21 31.25
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 92,742 57,425 -38.08 148 93 -37.16
2018-05-15 13F-HR Advisor Group, Inc. 7,000 7,000 0.00 11 11 0.00
2018-05-11 13F-HR SevenBridge Financial Group, LLC 125 125 0.00 0 0
2018-05-03 13F-HR MEEDER ASSET MANAGEMENT INC 1,283 1,414 10.21 2 2 0.00
2018-05-15 13F-HR Baker Brothers Advisors LP 950,000 950,000 0.00 1,520 1,558 2.50
2018-05-15 13F-HR UBS Group AG 0 5,000 0 8
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 21,772 7,485 -65.62 35 13 -62.86
2018-05-14 13F-HR CITIZENS & NORTHERN CORP 54,300 54,300 0.00 87 89 2.30
2018-05-14 13F-HR Stone Ridge Asset Management LLC 31,468 0 -100.00 50 0 -100.00
2018-05-15 13F-HR CREDIT SUISSE AG/ 16,629 21,572 29.73 26 36 38.46
2018-05-15 13F-HR Ameritas Investment Partners, Inc. 3,486 3,486 0.00 6 6 0.00
2018-05-15 13F-HR Kovack Advisors, Inc. 11,400 21,300 86.84 18 35 94.44
2018-05-11 13F-HR CITIGROUP INC 8,143 9,999 22.79 13 16 23.08
2018-05-10 13F-HR Myda Advisors Llc 22,113 0 -100.00 35 0 -100.00
2018-05-15 13F-HR LPL Financial LLC 21,162 22,462 6.14 34 37 8.82
2018-05-10 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 125,000 125,000 0.00 200 205 2.50
2017-08-08 13F-HR Airain ltd 0 39,080 0 90
2018-05-11 13F-HR DIMENSIONAL FUND ADVISORS LP 944,232 869,083 -7.96 1,511 1,425 -5.69
2018-05-14 13F-HR TIAA CREF INVESTMENT MANAGEMENT LLC 156,957 151,536 -3.45 251 249 -0.80
2018-05-15 13F-HR BARCLAYS PLC 18,324 20,820 13.62 29 34 17.24
2018-05-11 13F-HR BNP PARIBAS ARBITRAGE, SA 15,361 12,842 -16.40 24,578 21,061 -14.31
2018-05-04 13F-HR VICTORY CAPITAL MANAGEMENT INC 2,717 0 -100.00 4 0 -100.00
2018-04-26 13F-HR SIMPLEX TRADING, LLC 2,314 0 -100.00 3 0 -100.00
2018-07-19 13F-HR BOURGEON CAPITAL MANAGEMENT LLC 69,500 79,500 14.39 114 114 0.00
2018-05-15 13F-HR Voya Investment Management LLC 28,282 28,282 0.00 45 46 2.22
2018-05-07 13F-HR STATE OF WISCONSIN INVESTMENT BOARD 40,000 40,000 0.00 64 66 3.13
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 6,112 7,021 14.87 10 12 20.00
2018-05-14 13F-HR Renaissance Technologies LLC 12,900 143,300 1,010.85 21 235 1,019.05
2018-05-14 13F-HR Itau Unibanco Holding S.A. 1,696 6,243 268.10 3 10 233.33
2018-05-14 13F-HR PARAMETRIC PORTFOLIO ASSOCIATES LLC 59,583 72,821 22.22 95 119 25.26
2018-05-07 13F-HR AMERICAN INTERNATIONAL GROUP INC 37,788 37,423 -0.97 60 61 1.67
2018-05-11 13F-HR Cutler Group LP 2,400 2,400 0.00 3 3 0.00
2018-05-14 13F-HR ALLIANCEBERNSTEIN L.P. 45,400 45,400 0.00 73 74 1.37
2018-05-15 13F-HR Schonfeld Strategic Advisors LLC 150,000 0 -100.00 240 0 -100.00
2018-05-14 13F-HR FMR LLC / Fidelity 4,214,889 4,265,270 1.20 6,744 6,995 3.72
2018-05-09 13F-HR NORTHERN TRUST CORP 543,730 579,697 6.61 870 950 9.20
2018-05-14 13F-HR UNITED SERVICES AUTOMOBILE ASSOCIATION 169,829 172,203 1.40 272 282 3.68
2018-04-26 13F-HR SIMPLEX TRADING, LLC Call 55 45 -18.18 1 0 -100.00
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 402,312 413,256 2.72 643 677 5.29
2018-05-14 13F-HR PRICE T ROWE ASSOCIATES INC /MD/ 194,056 194,165 0.06 310 318 2.58
2017-02-10 13F-HR BlackRock Fund Advisors 1,936,501 2,159,505 11.52 13,071 12,698 -2.85
2018-05-15 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 10,761 424 -96.06 18 1 -94.44
2018-05-03 13F-HR AMERICAN CENTURY COMPANIES INC 84,587 0 -100.00 135 0 -100.00
2018-05-15 13F-HR GUGGENHEIM CAPITAL LLC 13,386 12,912 -3.54 22 21 -4.55
2017-10-31 13F-HR Nine Chapters Capital Management LLC 0 14,900 0 38
2018-05-14 13F-HR AMERIPRISE FINANCIAL INC 24,069 0 -100.00 39 0 -100.00
2018-05-15 13F-HR GOLDMAN SACHS GROUP INC 195,253 22,553 -88.45 312 37 -88.14
2018-05-10 13F-HR NEW YORK STATE COMMON RETIREMENT FUND 38,400 38,400 0.00 61 63 3.28
TRVN: Trevena Analysis and Research Report

2018-07-02 - Asif

Overview Trevena, Inc. is a biopharmaceutical company developing innovative therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Using its proprietary product platform, Trevena has identified and are developing the following product candidates: OLINVOTM (oliceridine) Injection: Trevena is developing OLINVO, a G protein biased ligand of the μ opioid receptor, for the management of moderate-to-severe acute pain where intravenous, or IV, administration is preferred. In February 2017, the company announced positive top-line results from its Phase 3 APOLLO-1 and APOLLO-2 pivotal efficacy studies of OLINVO in moderate-to-severe acute pain following bunionectomy and abdominoplasty, respectively. In both studies, all dose regimens achieved their primary endpoint of statistically greater analgesic efficacy than placebo, as measured by responder rate. In July 2017, the company announced that the company...

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Your Daily Pharma Scoop: Gemphire Zooms, Trevena Succeeds, Arsanis Falters

2018-07-01 seekingalpha
Discussion: Gemphire Therapeutics’ (GEMP) candidate Gemcabene met its Phase 2b primary endpoint in hypertriglyceridemia patients. The company reported significant reduction of up to 47% in patients against 27% for placebo-treated group. This drug candidate is the first oral therapy targeted at ~3.5M patients in the U.S. whose LDL-C or triglyceride level needs to be brought down to avoid further risk of developing acute pancreatitis. (18-2)

CUSIP: 89532E109